Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFB97P)

Drug Name
Dihydrotachysterol Drug Info
Synonyms
Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol
Indication
Disease Entry ICD 11 Status REF
Hypocalcemia 5B5K.1 Approved [1]
Hypoparathyroidism 5A50 Approved [2]
Hypophosphatemia Approved [3]
Intestinal hypomagnesemia 1 Approved [4]
Rickets 5B57 Approved [5]
Autosomal dominant hypocalcemia 5A50.0Y Investigative [6]
Therapeutic Class
Antihypoparathyroid Agents
Cross-matching ID
PubChem CID
5311071
ChEBI ID
CHEBI:4591
CAS Number
CAS 67-96-9
TTD Drug ID
DMFB97P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Vitamin D3 receptor (VDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergocalciferol DMHO0AR Hypoparathyroidism 5A50 Approved [8]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [9]
Calcidiol DMN4CV5 Hypophosphatemia Approved [8]
Doxercalciferol DM6FG1P Chronic kidney disease GB61 Approved [10]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [11]
Falecalcitrol DMBI9ZJ Hyperparathyroidism 5A51 Approved [12]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [13]
Paricalcitol DMYBV3G Hyperparathyroidism 5A51 Approved [14]
Seocalcitol DMKL9QO Rickets 5B57 Phase 3 [15]
S-06911 DMAYTIH Osteoporosis FB83.0 Phase 3 [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin D3 receptor (VDR) TTK59TV VDR_HUMAN Antagonist [7]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Hypoparathyroidism and pseudo-hypoparathyroidism. Br Med J. 1954 Apr 17;1(4867):903-9.
3 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study. J Clin Endocrinol Metab. 1996 Jun;81(6):2381-8.
4 Vitamin D resistance in magnesium deficiency. Am J Clin Nutr. 1976 Aug;29(8):854-8.
5 End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet. 1980 Mar 8;1(8167):504-6.
6 Feline thyroidectomy. A comparison of postoperative hypocalcemia associated with three different surgical techniques. Vet Surg. 1987 Sep-Oct;16(5):362-6.
7 In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
8 Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
9 Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
10 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
11 Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
12 Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
13 [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
14 New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
15 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
16 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.